Observations on serial radionuclide blood-flow studies in Paget's disease: concise communication.
Twenty-four symptomatic patients with symptoms of active Paget's disease of bone were evaluated, during the course of their therapy, a total of 71 times (24 baseline and 47 follow-up examinations) by serial alkaline phosphatase levels (AP), Tc-99m MDP bone scans, and radionuclide blood-flow studies. The flow study correlated with disease activity in all of the baseline studies and in at least 85% of the follow-up studies. In five patients (seven follow-up studies) the changes in local blood flow correctly anticipated the eventual rise or fall of AP. In comparison with the bone scan, the changes in blood flow preceded the bone-scan alterations or were more reliable indicators of disease activity in 12 of the 13 follow-up studies in which the results of the two examinations disagreed. We conclude that the radionuclide flow study provides useful additional clinical information in the management of Paget's disease.
D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000098:blood supply* / Q000000981:diagnostic imaging; D002116:Calcitonin / Q000627:therapeutic use; D004164:Diphosphonates; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D006940:Hyperemia / Q000000981:diagnostic imaging; D010001:Osteitis Deformans / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D008926:Plicamycin / Q000627:therapeutic use; D011877:Radionuclide Imaging; D012039:Regional Blood Flow; D013667:Technetium; D013669:Technetium Tc 99m Medronate
D004164:Diphosphonates; D013667:Technetium; D002116:Calcitonin; D000469:Alkaline Phosphatase; D012968:Etidronic Acid; D008926:Plicamycin; D013669:Technetium Tc 99m Medronate